MCID: BRN071
MIFTS: 54

Brain Injury

Categories: Neuronal diseases

Aliases & Classifications for Brain Injury

MalaCards integrated aliases for Brain Injury:

Name: Brain Injury 39 55

Classifications:



Summaries for Brain Injury

NINDS : 55 Traumatic brain injury (TBI), a form of acquired brain injury, occurs when a sudden trauma causes damage to the brain. TBI can result when the head suddenly and violently hits an object, or when an object pierces the skull and enters brain tissue.  Symptoms of a TBI can be mild, moderate, or severe, depending on the extent of the damage to the brain. A person with a mild TBI may remain conscious or may experience a loss of consciousness for a few seconds or minutes. Other symptoms of mild TBI include headache, confusion, lightheadedness, dizziness, blurred vision or tired eyes, ringing in the ears, bad taste in the mouth, fatigue or lethargy, a change in sleep patterns, behavioral or mood changes, and trouble with memory, concentration, attention, or thinking.  A person with a moderate or severe TBI may show these same symptoms, but may also have a headache that gets worse or does not go away, repeated vomiting or nausea, convulsions or seizures, an inability to awaken from sleep, dilation of one or both pupils of the eyes, slurred speech, weakness or numbness in the extremities, loss of coordination, and increased confusion, restlessness, or agitation.

MalaCards based summary : Brain Injury is related to neonatal hypoxic and ischemic brain injury and head injury. An important gene associated with Brain Injury is ASIC1 (Acid Sensing Ion Channel Subunit 1), and among its related pathways/superpathways are Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways and Neuroscience. The drugs Zinc and Mannitol have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and bone, and related phenotypes are behavior/neurological and cardiovascular system

Related Diseases for Brain Injury

Diseases related to Brain Injury via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 491)
# Related Disease Score Top Affiliating Genes
1 neonatal hypoxic and ischemic brain injury 34.1 BDNF ENO2 MBP
2 head injury 32.8 APOE ENO2 S100B
3 persistent vegetative state 32.4 APOE ENO2
4 periventricular leukomalacia 32.4 EPO IL6 MBP
5 aphasia 31.9 APOE BDNF MAPT
6 alzheimer disease 31.1 APOE BDNF CASP3 GFAP MAPT S100B
7 brain edema 31.0 AQP4 GFAP IL6
8 traumatic brain injury 30.9 APOE AQP4 BDNF CASP3 COMT DRD2
9 post-traumatic stress disorder 30.7 APOE BDNF COMT DRD2
10 status epilepticus 30.4 BDNF CASP3 ENO2 GFAP
11 substance abuse 30.3 BDNF COMT DRD2
12 spinal cord injury 30.2 AQP4 BDNF CASP3 GFAP IL6
13 mood disorder 30.1 BDNF COMT DRD2 IL6
14 psychotic disorder 29.9 BDNF COMT DRD2 S100B
15 akinetic mutism 29.9 ENO2 MAPT
16 stroke, ischemic 29.9 APOE AQP4 CASP3 ENO2 MBP
17 neurilemmoma 29.8 ENO2 GFAP S100B
18 personality disorder 29.8 BDNF COMT DRD2
19 hydrocephalus 29.7 APOE ENO2 GFAP IGF1 MAPT MBP
20 neuroaxonal dystrophy 29.6 ENO2 IGF1 MBP
21 eating disorder 29.6 BDNF COMT DRD2
22 sleep apnea 29.5 APOE IGF1 IL6 S100B
23 disease of mental health 29.5 APOE BDNF COMT DRD2 IL6 MAPT
24 generalized anxiety disorder 29.4 BDNF COMT DRD2
25 vascular dementia 29.4 APOE MAPT MBP
26 multiple sclerosis 29.3 APOE AQP4 BDNF GFAP IL6 MBP
27 neuromyelitis optica 29.3 AQP4 GFAP IL6 MBP
28 peripheral nervous system disease 29.3 AQP4 IL6 MBP
29 chiari malformation 29.3 GFAP MBP
30 major depressive disorder 29.3 APOE BDNF COMT DRD2 IL6
31 amyotrophic lateral sclerosis 1 29.2 BDNF CASP3 GFAP IGF1 MAPT
32 brain cancer 29.0 AQP4 CASP3 ENO2 GFAP MBP
33 parkinson disease, late-onset 28.6 APOE BDNF CASP3 COMT DRD2 MAPT
34 central nervous system disease 28.1 APOE AQP4 BDNF CASP3 GFAP IL6
35 moderate and severe traumatic brain injury 12.5
36 pseudobulbar affect 11.3
37 ocular motor apraxia 11.3
38 agnosia 11.3
39 locked-in syndrome 11.3
40 dysphagia 11.2
41 epilepsy 11.2
42 cerebral hypoxia 11.2
43 dementia pugilistica 11.2
44 shaken baby syndrome 11.2
45 post-traumatic epilepsy 11.2
46 cerebral atrophy 11.2
47 apraxia 11.2
48 swallowing disorders 11.2
49 west syndrome 11.1
50 tremor 11.1

Graphical network of the top 20 diseases related to Brain Injury:



Diseases related to Brain Injury

Symptoms & Phenotypes for Brain Injury

MGI Mouse Phenotypes related to Brain Injury:

47 (show all 18)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.45 APOE AQP4 ASIC1 BDNF CASP3 COMT
2 cardiovascular system MP:0005385 10.35 APOE AQP4 CASP3 COMT DRD2 EPO
3 growth/size/body region MP:0005378 10.35 APOE AQP4 BDNF CASP3 DRD2 ENO2
4 cellular MP:0005384 10.34 APOE BDNF CASP3 DRD2 ENO2 EPO
5 homeostasis/metabolism MP:0005376 10.34 APOE AQP4 BDNF CASP3 COMT DRD2
6 nervous system MP:0003631 10.27 APOE AQP4 ASIC1 BDNF CASP3 COMT
7 hematopoietic system MP:0005397 10.25 APOE AQP4 CASP3 COMT DRD2 EPO
8 mortality/aging MP:0010768 10.25 APOE AQP4 BDNF CASP3 DRD2 EPO
9 immune system MP:0005387 10.22 APOE AQP4 CASP3 COMT DRD2 EPO
10 integument MP:0010771 10.16 APOE BDNF CASP3 DRD2 EPO IGF1
11 digestive/alimentary MP:0005381 10.15 APOE AQP4 BDNF CASP3 DRD2 GFAP
12 muscle MP:0005369 10.01 APOE CASP3 DRD2 EPO GFAP IGF1
13 hearing/vestibular/ear MP:0005377 10 APOE AQP4 BDNF CASP3 IGF1 MBP
14 normal MP:0002873 9.97 BDNF DRD2 EPO GFAP IGF1 MAPT
15 renal/urinary system MP:0005367 9.91 APOE AQP4 CASP3 COMT DRD2 IGF1
16 respiratory system MP:0005388 9.9 APOE AQP4 BDNF CASP3 COMT DRD2
17 taste/olfaction MP:0005394 9.43 APOE BDNF CASP3 DRD2 ENO2 MAPT
18 vision/eye MP:0005391 9.28 APOE AQP4 BDNF CASP3 GFAP IL6

Drugs & Therapeutics for Brain Injury

Drugs for Brain Injury (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 697)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Zinc Approved, Investigational Phase 4,Phase 3,Phase 2 7440-66-6 32051
2
Mannitol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 69-65-8 453 6251
3
Midazolam Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1 59467-70-8 4192
4
Morphine Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 57-27-2 5288826
5
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
6
Citalopram Approved Phase 4,Phase 2,Not Applicable,Early Phase 1 59729-33-8 2771
7
Methylphenidate Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 113-45-1 4158
8
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 62-31-7, 51-61-6 681
9
Amantadine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 768-94-5 2130
10
Clopidogrel Approved Phase 4 120202-66-6, 113665-84-2 60606
11
Atorvastatin Approved Phase 4,Phase 1,Phase 2 134523-00-5 60823
12
tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1401-55-4
13
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 113775-47-6 68602 5311068
14
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 94-09-7, 1994-09-7 2337
15
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2078-54-8 4943
16
Sevoflurane Approved, Vet_approved Phase 4,Phase 2,Phase 1,Not Applicable 28523-86-6 5206
17
Sufentanil Approved, Investigational Phase 4,Phase 2 56030-54-7 41693
18
Remifentanil Approved Phase 4,Not Applicable 132875-61-7 60815
19
Cisatracurium Approved Phase 4 96946-41-7
20
Atracurium Approved, Experimental, Investigational Phase 4 64228-79-1 47319
21
Aspirin Approved, Vet_approved Phase 4,Phase 2 50-78-2 2244
22
Levodopa Approved Phase 4,Phase 1,Phase 2 59-92-7 6047
23
Clonazepam Approved, Illicit Phase 4 1622-61-3 2802
24
Valproic Acid Approved, Investigational Phase 4,Phase 3,Phase 1,Not Applicable 99-66-1 3121
25
Tranexamic Acid Approved Phase 4,Phase 3,Phase 2 1197-18-8 5526
26
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
27
Memantine Approved, Investigational Phase 4,Phase 2,Not Applicable 19982-08-2 4054
28
Etomidate Approved Phase 4 33125-97-2 36339 667484
29
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 2,Not Applicable 437-38-7 3345
30
Norepinephrine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 51-41-2 439260
31
Testosterone Approved, Experimental, Investigational Phase 4,Phase 2,Not Applicable 58-22-0, 481-30-1 6013 10204
32
Enoxaparin Approved Phase 4,Phase 1 9005-49-6 772
33
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 64-17-5 702
34
Acetylcholine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 51-84-3 187
35
Caffeine Approved Phase 4,Phase 3,Not Applicable 58-08-2 2519
36
Sodium Citrate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 68-04-2
37
Acetaminophen Approved Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1 103-90-2 1983
38
Donepezil Approved Phase 4,Phase 3,Phase 1,Phase 2 120014-06-4 3152
39
Lamotrigine Approved, Investigational Phase 4,Phase 1,Phase 2 84057-84-1 3878
40
Racepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 329-65-7 838
41
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 50-23-7 5754
42
Hydrocortisone acetate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 50-03-3
43
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-43-4 5816
44
Ibuprofen Approved Phase 4,Phase 3,Phase 2,Not Applicable 15687-27-1 3672
45
Exenatide Approved, Investigational Phase 4,Not Applicable 141758-74-9 15991534
46
Propranolol Approved, Investigational Phase 4,Phase 2,Phase 1 525-66-6 4946
47
Rivastigmine Approved, Investigational Phase 4,Phase 3 123441-03-2 77991
48
Testosterone undecanoate Approved, Investigational Phase 4,Phase 2 5949-44-0
49
Testosterone enanthate Approved Phase 4,Phase 2 315-37-7 9416
50
Methyltestosterone Approved Phase 4,Phase 2 58-18-4 6010

Interventional clinical trials:

(show top 50) (show all 2723)
# Name Status NCT ID Phase Drugs
1 Effect of Rozerem on Sleep Among People With Traumatic Brain Injury Unknown status NCT01207050 Phase 4 Ramelteon
2 Intensive Versus Nonintensive Insulin Therapy for Hyperglycemia After Traumatic Brain Injury Unknown status NCT02161055 Phase 4 Insulin
3 The CAPTAIN Trial: Cerebrolysin Asian Pacific Trial in Acute Brain Injury and Neurorecovery Unknown status NCT01606111 Phase 4 Cerebrolysin;0.9% NaCl, saline
4 A Clinical Trial of the Effect of Midazolam on the Cerebral Metabolism and Inflammatory Response in Patients With Moderate and Severe Traumatic Brain Injury Unknown status NCT02071407 Phase 4 Midazolam;Placebo
5 Normothermia in Patients With Acute Cerebral Damage Unknown status NCT00491192 Phase 4 Diclofenac
6 Antidepressant Maintenance in Traumatic Brain Injury Unknown status NCT00162916 Phase 4 citalopram;Placebo
7 Methylphenidate for Attention Problems After Pediatric TBI Unknown status NCT01933217 Phase 4 Methylphenidate;Placebo
8 Is Sensory Stimulation Effective in Reducing Time Spent in a Coma or Vegetative State Unknown status NCT00163878 Phase 4
9 Amantadine for Treatment of Symptoms of the Post-Traumatic Confusional State Unknown status NCT00693121 Phase 4 Amantadine hydrochloride;Placebo capsule
10 Clopidogrel and Atorvastatin Treatment During Carotid Artery Stenting Unknown status NCT01572623 Phase 4 Clopidogrel;Atorvastatin
11 The Effect of Dexmedetomidine to Cognition of Geriatrics in Prolonged Surgery Unknown status NCT02123355 Phase 4 Induction of anesthesia;Sevoflurane, remifentanil ,vecuronium;Dexmedetomidine;Placebo
12 Treatment of Intracranial Hypertension of Severe Tramatic Brain Injured Patients. Physiopathologic Effects of Neuromuscular Blocking Agents Unknown status NCT02404779 Phase 4 cisatracurium besilate
13 Efficiency of a Small-peptide Enteral Feeding Formula Compared to a Whole-protein Formula Unknown status NCT01833624 Phase 4
14 Does Discontinuation of Aspirin Treatment Following Head Trauma Decrease the Incidence of Chronic Subdural Hematoma? Unknown status NCT01470040 Phase 4 discontinuation of aspirin therapy;continuation of aspirin therapy
15 Intensive Insulin Therapy for Strict Glycemic Control in Neurosurgical Patients: Safety and Efficacy Unknown status NCT00505505 Phase 4 Insulin (Actrapid)
16 Dopamine Treatment in Children With Cerebral Palsy With Dystonia- A Double Blind Controlled Study Unknown status NCT01361373 Phase 4 L- DOPA;placebo
17 The Benefit of Prophylactic Anticonvulsant in Post Cardiac Arrest Syndrome With Induced Mild Hypothermia Unknown status NCT01083784 Phase 4 Use of prophylactic anticonvulsants (valproate, clonazepam);Control group
18 TXA in the EMS on the Helicopter and the Ambulance Unknown status NCT02354885 Phase 4 Tranexamic Acid
19 Tramadol Extended-Release (ER) for Posttraumatic Stress Disorder (PTSD) Unknown status NCT01517711 Phase 4 Tramadol;Placebo
20 Creative Therapy to Affect Stroke Outcomes Unknown status NCT01455155 Phase 4
21 "Equistasi" and Gait in Hemiparesis Unknown status NCT02714478 Phase 4
22 Memantine and Constraint-Induced Language Therapy in Chronic Poststroke Aphasia:A Randomized Controlled Trial Unknown status NCT00196703 Phase 4 memantine
23 Delayed Vasospasm After Aneurysm With the Standardization Treatment of Traditional Chinese Medicine Unknown status NCT01840761 Phase 4 herbal drug;placebo
24 A Comparison Between Propofol and Etomidate in Hysteroscopy on Effect of Postoperative Sedation and Cognitive Function in Elderly Patients Unknown status NCT02147678 Phase 4 Etomidate;Propofol;Remifentanil;Anesthesia induction
25 Sevoflurane Decreases the Risk of Postoperative Delirium After Cerebral Hypoxemia During Surgery Unknown status NCT02133638 Phase 4 Sevoflurane;Propofol
26 The Effect on the Older's Cognition of Dual-loop Target Controlled Infusion Guided by Narcotrend Index Unknown status NCT03010098 Phase 4
27 Consequence of Dexmedetomidine on Emergence Deliruim After Sevoflurane Anesthesia in Children With Cerebral Palsy Unknown status NCT02244515 Phase 4 dexmedetomidine
28 Effects of Functional Electrical Stimulation on Gait in Children With Cerebral Palsy Unknown status NCT02462018 Phase 4
29 Intravenous Exenatide in Patients With Acute Brain Injury Completed NCT02058940 Phase 4 Exenatide
30 Using Propranolol in Traumatic Brain Injury to Reduce Sympathetic Storm Phenomenon Completed NCT03401515 Phase 4 Propranolol Hydrochloride 1 MG/ML
31 An Extension Study Evaluating the Efficacy and Safety of Rivastigmine in Patients With Traumatic Brain Injury (TBI) With Persistent Cognitive Deficits Completed NCT00219245 Phase 4 Rivastigmine
32 Pediatric Traumatic Brain Injury: Methylphenidate Effects on Early Recovery Completed NCT00035139 Phase 4 methylphenidate
33 Beta Blockade in in Traumatic Brain Injury Completed NCT02957331 Phase 4 Propranolol
34 Pharmacological Intervention in Depression After Traumatic Brain Injury Completed NCT00205491 Phase 4 Venlafaxine
35 The Relationship Between Traumatic Brain Injury and Dopamine (a Chemical in the Brain) Completed NCT02015949 Phase 4 Methylphenidate;Placebo
36 The Study of Cognitive Rehabilitation Effectiveness for Mild Traumatic Brain Injury Completed NCT01339806 Phase 4
37 Neuroendocrine Dysfunction in Traumatic Brain Injury: Effects of Testosterone Therapy Completed NCT01201863 Phase 4 Androgel (Testosterone Gel);Androgel Placebo
38 Anterior Pituitary Hormone Replacement in Traumatic Brain Injury Completed NCT00957671 Phase 4 Recombinant human growth hormone
39 Depression and Traumatic Brain Injury Completed NCT00254007 Phase 4 citalopram (celexa)
40 The Use of Low Molecular Weight Heparin in Traumatic Brain Injury Completed NCT00170378 Phase 4 Enoxaparin
41 Optimized Therapy in Severe Traumatic Brain Injured Patients Completed NCT02130674 Phase 4 Dipeptiven
42 Effect of Erythropoietin on Preterm Brain Injury Completed NCT02036073 Phase 4 recombinant human erythropoietin
43 Bispectral Index Value Changes During Induction and Surgical Decompression in Head Injury Patients Completed NCT03480880 Phase 4
44 Assess Safety and Efficacy of Levetiracetam(LEV;Keppra)for Seizure Prevention Completed NCT00618436 Phase 4 Levetiracetam;Phenytoin
45 Topiramate Treatment of Hazardous and Harmful Alcohol Use in Veterans With TBI Completed NCT01750268 Phase 4 Topiramate;Placebo
46 Simvastatin for mTBI Completed NCT01952288 Phase 4 simvastatin;Placebo Oral Tablet
47 Safety, Tolerability and Effectiveness of Nuedexta in the Treatment of Pseudobulbar Affect (PBA) Completed NCT01799941 Phase 4 Nuedexta (DM 20 mg/Q 10 mg)
48 Comparative Efficacy of Three Preparations of Botox-A in Treating Spasticity Completed NCT00178646 Phase 4 Botox
49 Melatonin to Prevent Brain Injury in Unborn Growth Restricted Babies Completed NCT01695070 Phase 4 Melatonin
50 BOTOX® Versus Zanaflex® for the Treatment of Post-Stroke or Traumatic Brain Injury Upper Limb Spasticity Completed NCT00430196 Phase 4 BOTOX®;Zanaflex®

Search NIH Clinical Center for Brain Injury

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Brain Injury cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Brain Injury:
Hematopoietic stem cells for treatment of ischemic brain injury
Embryonic/Adult Cultured Cells Related to Brain Injury:
Bone marrow-derived hematopoietic stem cells (family)

Genetic Tests for Brain Injury

Anatomical Context for Brain Injury

MalaCards organs/tissues related to Brain Injury:

42
Brain, Testes, Bone, Heart, Eye, Spinal Cord, Pituitary

Publications for Brain Injury

Articles related to Brain Injury:

(show top 50) (show all 6446)
# Title Authors Year
1
Acid sphingomyelinase deficiency protects mitochondria and improves function recovery after brain injury. ( 30662008 )
2019
2
Alcohol dependence treating agent, acamprosate, prevents traumatic brain injury-induced neuron death through vesicular zinc depletion. ( 30731068 )
2019
3
Memantine: From Alzheimer Disease to Traumatic Brain Injury. ( 30471450 )
2019
4
Quercetin mitigates anxiety-like behavior and normalizes hypothalamus-pituitary-adrenal axis function in a mouse model of mild traumatic brain injury. ( 30882424 )
2019
5
The blockade of corticotropin-releasing factor 1 receptor attenuates anxiety-related symptoms and hypothalamus-pituitary-adrenal axis reactivity in mice with mild traumatic brain injury. ( 30883392 )
2019
6
Severe Perinatal Hypoxic-Ischemic Brain Injury Induces Long-Term Sensorimotor Deficits, Anxiety-Like Behaviors and Cognitive Impairment in a Sex-, Age- and Task-Selective Manner in C57BL/6 Mice but Can Be Modulated by Neonatal Handling. ( 30814939 )
2019
7
Long-Term Effects of Traumatic Brain Injury on Anxiety-Like Behaviors in Mice: Behavioral and Neural Correlates. ( 30728770 )
2019
8
Risks of bipolar disorder, depressive disorder, and traumatic brain injury among siblings of patients with attention-deficit hyperactivity disorder. ( 30419534 )
2019
9
Deficiency of plasminogen activator inhibitor type 2 limits brain edema formation after traumatic brain injury. ( 30755137 )
2019
10
Effects of Conivaptan versus Mannitol on Post-Ischemic Brain Injury and Edema. ( 30911255 )
2019
11
Echinacoside Alleviates Hypoxic-Ischemic Brain Injury in Neonatal Rat by Enhancing Antioxidant Capacity and Inhibiting Apoptosis. ( 30911982 )
2019
12
Impact of television on nutritional intake in communal dining room settings among those with acquired brain injury: A pilot study. ( 30912282 )
2019
13
Role of quetiapine in protection of neurodegeneration after traumatic brain injury. ( 30913942 )
2019
14
Neuroprotective effects of inter-alpha inhibitor proteins after hypoxic-ischemic brain injury in neonatal rats. ( 30914159 )
2019
15
Hyperglycemia-induced oxidative brain injury: Therapeutic effects of Cola nitida infusion against redox imbalance, cerebellar neuronal insults, and upregulated Nrf2 expression in type 2 diabetes rats. ( 30914353 )
2019
16
Novel Mouse Tauopathy Model for Repetitive Mild Traumatic Brain Injury: Evaluation of Long-Term Effects on Cognition and Biomarker Levels After Therapeutic Inhibition of Tau Phosphorylation. ( 30915013 )
2019
17
Melatonin in Hypoxic-Ischemic Brain Injury in Term and Preterm Babies. ( 30915118 )
2019
18
Cognitive, Emotional, and Physical Functioning as Predictors of Paid Employment in People With Stroke, Traumatic Brain Injury, and Spinal Cord Injury. ( 30915962 )
2019
19
Noninvasive magnetic resonance imaging stratifies injury severity in a rodent model of male juvenile traumatic brain injury. ( 30916808 )
2019
20
Antidepressants and the risk of traumatic brain injury in the elderly: differences between individual agents. ( 30858730 )
2019
21
Prognosis of 6-month Glasgow Outcome Scale in severe traumatic brain injury using hospital admission characteristics, injury severity characteristics, and physiological monitoring during the first day post-injury. ( 30860434 )
2019
22
Exosomes from MiR-21-5p-Increased Neurons Play a Role in Neuroprotection by Suppressing Rab11a-Mediated Neuronal Autophagy In Vitro After Traumatic Brain Injury. ( 30860987 )
2019
23
Brain interrupted: Early life traumatic brain injury and addiction vulnerability. ( 30862466 )
2019
24
How Do Parents Influence Child Disruptive Behavior After Acquired Brain Injury? Evidence From a Mediation Model and Path Analysis. ( 30864536 )
2019
25
Drug-Induced Parkinsonism Manifesting as Gait Freezing in a Patient With Traumatic Brain Injury: A Case Report. ( 30865004 )
2019
26
Deep Brain Stimulation for Recovery of Consciousness in Minimally Conscious Patients After Traumatic Brain Injury: A Systematic Review. ( 30865342 )
2019
27
Using audit and feedback to increase clinician adherence to clinical practice guidelines in brain injury rehabilitation: A before and after study. ( 30865685 )
2019
28
Plasma osteopontin may predict neuroinflammation and the severity of pediatric traumatic brain injury. ( 30866741 )
2019
29
Human parthenogenetic neural stem cell grafts promote multiple regenerative processes in a traumatic brain injury model. ( 30867814 )
2019
30
Quantitative multivoxel proton MR spectroscopy for the identification of white matter abnormalities in mild traumatic brain injury: Comparison between regional and global analysis. ( 30868703 )
2019
31
Promoting mental health in traumatic brain injury using single-session Behavioural Activation and SMS messaging: A randomized controlled trial. ( 30870102 )
2019
32
Postconcussion symptom reporting is not associated with diffusion tensor imaging findings in the subacute to chronic phase of recovery in military service members following mild traumatic brain injury. ( 30871410 )
2019
33
Inhibition of COX2/PGD2-Related Autophagy Is Involved in the Mechanism of Brain Injury in T2DM Rat. ( 30873010 )
2019
34
The Role of Connexin and Pannexin Channels in Perinatal Brain Injury and Inflammation. ( 30873043 )
2019
35
Health Care Utilization and Costs of Veterans Evaluated for Traumatic Brain Injury through Telehealth. ( 30874499 )
2019
36
Calpain inhibitor MDL28170 improves the transplantation-mediated therapeutic effect of bone marrow-derived mesenchymal stem cells following traumatic brain injury. ( 30876457 )
2019
37
Modified Glasgow Coma Scale using Serum Factors as a Prognostic Model in Traumatic Brain Injury'. ( 30876987 )
2019
38
Hypertonic Saline is Superior to Mannitol for the Combined Effect on Intracranial Pressure and Cerebral Perfusion Pressure Burdens in Patients With Severe Traumatic Brain Injury. ( 30877299 )
2019
39
Pathophysiological Insights into Spreading Depolarization in Severe Traumatic Brain Injury. ( 30877553 )
2019
40
Cost of Military Eye Injury and Vision Impairment Related to Traumatic Brain Injury: 2001-2017: Corrigendum. ( 30877798 )
2019
41
Assessment of Brain Injury and Brain Volumes after Posthemorrhagic Ventricular Dilatation: A Nested Substudy of the Randomized Controlled ELVIS Trial. ( 30878207 )
2019
42
Reply to: Optic nerve sheath diameter measurement in hypoxic ischaemic brain injury after cardiac arrest. ( 30878373 )
2019
43
Optic nerve sheath diameter measurement in hypoxic ischaemic brain injury after cardiac arrest. ( 30878376 )
2019
44
Rhodiola crenulata attenuates apoptosis and mitochondrial energy metabolism disorder in rats with hypobaric hypoxia-induced brain injury by regulating the HIF-1α/microRNA 210/ISCU1/2(COX10) signaling pathway. ( 30878546 )
2019
45
Comparison of equiosmolar dose of hyperosmolar agents in reducing intracranial pressure-a randomized control study in pediatric traumatic brain injury. ( 30879126 )
2019
46
Mild Traumatic Brain Injury and Psychopathology in Adolescence: Evidence From the Project on Human Development in Chicago Neighborhoods. ( 30879882 )
2019
47
Incidence and mortality of moderate and severe traumatic brain injury in children: A ten year population-based cohort study in Norway. ( 30879962 )
2019
48
Myeloid-Derived Suppressor Cells Infiltrate the Brain and Suppress Neuroinflammation in a Mouse Model of Focal Traumatic Brain Injury. ( 30880103 )
2019
49
Survey response burden in caregivers of civilians and service members/veterans with traumatic brain injury. ( 30881163 )
2019
50
Glycine Protects against Hypoxic-Ischemic Brain Injury by Regulating Mitochondria-Mediated Autophagy via the AMPK Pathway. ( 30881590 )
2019

Variations for Brain Injury

Expression for Brain Injury

Search GEO for disease gene expression data for Brain Injury.

Pathways for Brain Injury

GO Terms for Brain Injury

Cellular components related to Brain Injury according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 dendrite GO:0030425 9.77 APOE BDNF COMT DRD2 MAPT
2 axon GO:0030424 9.72 BDNF COMT DRD2 MAPT UCHL1
3 myelin sheath GO:0043209 9.56 ENO2 GFAP MBP UCHL1
4 glial cell projection GO:0097386 9.4 GFAP MAPT
5 cell body GO:0044297 9.26 COMT EPO GFAP MAPT
6 neuronal cell body GO:0043025 9.17 APOE CASP3 ENO2 MAPT MBP S100B
7 phosphopyruvate hydratase complex GO:0000015 9.16 ENO1 ENO2
8 extracellular space GO:0005615 10.03 APOE BDNF ENO1 ENO2 EPO IGF1

Biological processes related to Brain Injury according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.65 BDNF EPO IGF1 IL6 MAPT
2 axonogenesis GO:0007409 9.58 DRD2 S100B UCHL1
3 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.5 EPO IGF1 IL6
4 axon development GO:0061564 9.46 GFAP MAPT
5 dopamine metabolic process GO:0042417 9.43 COMT DRD2
6 axonal transport of mitochondrion GO:0019896 9.37 MAPT UCHL1
7 response to glucocorticoid GO:0051384 9.33 CASP3 IL6 S100B
8 long-term synaptic potentiation GO:0060291 9.13 GFAP S100B SLC24A2
9 memory GO:0007613 9.02 ASIC1 BDNF MAPT S100B SLC24A2

Molecular functions related to Brain Injury according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 lipoprotein particle binding GO:0071813 8.96 APOE MAPT
2 phosphopyruvate hydratase activity GO:0004634 8.62 ENO1 ENO2
3 protein binding GO:0005515 10.09 APOE AQP4 ASIC1 CASP3 COMT DRD2

Sources for Brain Injury

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....